Taking Charge — Biotechs Already Approaching Novartis to Partner on ‘Game Changing’ CAR-T Platform

With the first generation of CAR-T therapies having shaken up the cancer space, all eyes are on what comes next. So it shouldn’t be a surprise that biotechs have already been in touch with Novartis to see whether they can jump onto the Swiss pharma’s T-Charge platform.